Blood Cancer Journal

Article	Citations
CAR-T cell therapy: current limitations and potential strategies	886
Acute myeloid leukemia: current progress and future directions	310
Multiple myeloma current treatment algorithms	177
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma	132
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)	124
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple m	122
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies	100
New directions for emerging therapies in acute myeloid leukemia: the next chapter	96
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment	95
CAR T-cell therapy in multiple myeloma: more room for improvement	95
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia	93
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study	88
Acute promyelocytic leukemia current treatment algorithms	79
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report	78
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia	78
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups	77
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies	74
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm	74
Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century	68
Chromosome 1q21 abnormalities in multiple myeloma	65
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma	65
The high cost of prescription drugs: causes and solutions	63
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage	63
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm	62
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study	62

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma	61
Extramedullary disease in multiple myeloma: a systematic literature review	58
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response	57
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality	53
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up	50
Core binding factor acute myelogenous leukemia-2021 treatment algorithm	50
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis	49
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab	49
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)	48
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study	47
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy	47
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis	46
Genetic and epigenetic determinants of diffuse large B-cell lymphoma	45
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma	45
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia	44
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life	44
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies	43
Extramedullary disease in multiple myeloma	43
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis	41
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantati	41
Diffuse large B-cell lymphoma: new targets and novel therapies	40
Immune-based therapies in the management of multiple myeloma	38
Comprehensive Review of AL amyloidosis: some practical recommendations	38
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study	38
CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma	36
B-cell maturation antigen expression across hematologic cancers: a systematic literature review	36
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis	35
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis	34
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse	34
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results	34
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment	34
Management of chronic myeloid leukemia in 2023 – common ground and common sense	34
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden	33
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements	33
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial	32
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)	32
Venetoclax for the treatment of translocation (11;14) AL amyloidosis	32
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML	31
Differentiation therapy for myeloid malignancies: beyond cytotoxicity	31
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up	30
A clinical perspective on plasma cell leukemia; current status and future directions	30
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	30
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden	30
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia	30
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab	29
A simple additive staging system for newly diagnosed multiple myeloma	29
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia	29
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma	29
Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing	28
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience	28

CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program	28
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma	28
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo	28
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma	27
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice	27
Mutations and thrombosis in essential thrombocythemia	27
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns	27
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021	27
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation	27
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study	27
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions	27
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine	27
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies	26
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up	26
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points	26
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma	26
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia	26
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07	26
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19	25
Impact of COVID-19 in patients with multiple myeloma based on a global data network	25
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis	24
Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center	24
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019	24
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review	24
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program	23
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression	23
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML	23
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study	23
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells	23
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients	23
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy	23
A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells	22
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	22
Financial toxicity in hematological malignancies: a systematic review	22
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study	22
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies	22
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia	22
Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma	21
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication	21
Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome	21
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia	20
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	20
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib	20
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients	20
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia	20
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL	20
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities	20
“Direct to Drug” screening as a precision medicine tool in multiple myeloma	20
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma	19
Global burden of hematologic malignancies and evolution patterns over the past 30 years	19
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients	19
Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms	19
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	19
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update	18
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera	18
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis	18
Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	18
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis	18
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma	17
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy	17
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype	17
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL	17
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement	17
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins	17
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	17
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients	17
Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia	16
Therapeutic targeting of the inflammasome in myeloid malignancies	16
Genomic characterization of functional high-risk multiple myeloma patients	16
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma	16
Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism	16
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study	16
DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma	16
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients	16
Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment	16
Preclinical development of CD126 CAR-T cells with broad antitumor activity	16
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study	15
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	15
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia	15
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	15

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib	15
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents	15
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	15
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)	15
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial	14
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT	14
HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias	14
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action	14
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies	14
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma	14
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	14
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients	14
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis	14
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia	14
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome	13
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies	13
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients	13
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation	13
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota	13
Infectious complications of bispecific antibody therapy in patients with multiple myeloma	13
Smoldering multiple myeloma current treatment algorithms	13
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia	13
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma	13
Cutaneous manifestations of monoclonal gammopathy	13
FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome	13
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial	13
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy	13